Macular degeneration is the number one cause of blindness among seniors aged 65 and older. The disease occurs as aging damages the light-sensitive portion of the retina called the macula, limiting its ability to process detailed images. Patients with macular degeneration typically experience blurry vision and blind spots in their fields of vision.
Current treatments for macular degeneration involve monthly injections. However, many patients may not be consistent with their treatments. Thankfully, a new therapy is showing great promise in treating macular degeneration. This is gene therapy.
Gene therapy for macular degeneration involves genetically modified strains of the non-pathogenic adeno-associated virus (AAV). Doctors deploy AAV to carry a code into retinal cells, enabling them to produce a protein that reduces inflammation and counteracts harmful agents. This helps the retina function normally.
While the treatment is still developing for conditions such as wet and dry macular degeneration and diabetic retinopathy, early clinical trials are promising, especially in reducing the number of injections the patient requires. Medical professionals are continuously developing the treatment. People interested in participating in a clinical trial can talk to their doctor at Retina Associates for further information.